Imagine facing one of the most stubborn foes in cancer treatment: microsatellite-stable metastatic colorectal cancer, where standard treatments often lose their edge after the first few rounds. This condition affects nearly 95% of colorectal cancer cases, resists immunotherapy, and leaves doctors relying on options like regorafenib or trifluridine/tipiracil—drugs that offer only modest help but come with significant side effects (as noted in Grothey et al., Lancet, 2013). Enter zanzalintinib, a cutting-edge multi-kinase inhibitor from Exelixis, sparking hope that we might finally crack the code on resistance tied to blood vessel growth and tumor surroundings in these tough cases. But here's where it gets controversial—could this drug truly revolutionize care, or is it just another costly attempt in a field starved for real progress? Let's dive in to understand why this matters for patients and experts alike.
For those new to this, colorectal cancer starts in the colon or rectum and can spread to other parts of the body, becoming 'metastatic.' Microsatellite-stable (MSS) means the cancer's DNA repair system works normally, making it harder for the immune system to spot and attack the tumors. Unlike some cancers that respond well to newer therapies, MSS colorectal cancer often ignores immunotherapies, creating a pressing need for better options. And this is the part most people miss: Zanzalintinib (formerly known as XL092) is designed to target this gap head-on.
To grasp how it works, think of it as a savvy blocker in the cell's communication network. Zanzalintinib is an oral medication that inhibits tyrosine kinases, specifically aiming at VEGFR2, MET, AXL, and TAM family members. These proteins play key roles in building new blood vessels (angiogenesis), helping tumors invade tissues, spread metastases, and even evade the immune system. By hitting VEGFR2 and MET together, it tackles evasion tactics that older anti-angiogenic drugs couldn't fully address. Plus, shutting down AXL helps prevent epithelial-mesenchymal transition—a change that turns cells more aggressive and resistant to treatment. Early studies show zanzalintinib has a shorter time in the body and better precision in its targeting, potentially leading to steadier effects and fewer side effects than its predecessor, cabozantinib (Gao et al., Clin Cancer Res, 2021). For beginners, imagine angiogenesis as the cancer's way of building its own highways for nutrients; blocking it starves the tumor while making it more visible to the body's defenses.
Now, why does MSS colorectal cancer seem to respond to zanzalintinib? This subtype is notoriously aggressive, 'cold' to the immune system, and stubbornly resistant to checkpoint inhibitors—those therapies that unleash immune cells. Picture it: low genetic mutations mean fewer flags for the immune system to recognize, coupled with heavy reliance on blood vessel growth, exclusion of immune cells, strong signals for cancer spread (epithelial-mesenchymal transition), and boosted activity in MET and AXL pathways. Zanzalintinib directly counters these by cutting back on blood vessel formation and reversing immune evasion driven by MET and AXL. The result? Less oxygen deprivation in tumors (hypoxia), better infiltration by killer T-cells, reduced metastatic tendencies, and an overall 'warming' of the tumor to make it more responsive to treatments. In essence, it gradually transforms these chilly, hard-to-treat cancers into warmer, more vulnerable ones—a clever trick that could open doors to combined therapies down the line.
The proof of concept came from the STELLAR-303 trial, a phase III study testing zanzalintinib against the current standard, regorafenib, in patients with MSS metastatic colorectal cancer who'd already tried multiple treatments: fluoropyrimidines, oxaliplatin, irinotecan, bevacizumab, and anti-EGFR drugs for certain genetic profiles. This group represents a challenging, heavily treated population with few alternatives left. Patients were randomly assigned to either zanzalintinib or regorafenib, a VEGF-focused drug.
But here's where it gets intriguing: STELLAR-303 showed zanzalintinib not only extended overall survival and progression-free survival over regorafenib but did so consistently across subgroups, including those with liver metastases—a group where immunotherapy often falls short (STELLAR-303 Investigators, ASCO GI, 2025). While exact numbers await full publication, researchers highlighted meaningful gains in controlling the disease, with longer-lasting responses and fewer dropouts early on. This marks a rare win in MSS colorectal cancer, where progress has stalled for years. Controversially, some might argue that extending life by months is worthwhile, but is it enough to justify the costs and efforts, especially when broader access remains an issue?
Safety-wise, zanzalintinib follows the pattern of multi-target anti-angiogenic drugs, with common side effects like high blood pressure, tiredness, diarrhea, and hand-foot syndrome. Yet, these seem more controllable than with regorafenib, which is plagued by severe hand-foot issues and stomach problems. The drug's refined targeting and quicker clearance from the body allow for more consistent dosing and easier adjustments. Fewer severe (grade 3 or higher) side effects occurred, and dose reductions were less common in the zanzalintinib group (STELLAR-303 Investigators, ASCO GI, 2025). This could mean better adherence and longer treatment periods—crucial for patients in advanced stages. For example, while regorafenib might force many to stop due to skin pain on hands and feet, zanzalintinib's profile might let patients stay on track, improving quality of life.
Clinically, zanzalintinib tackles old problems in MSS metastatic colorectal cancer by zeroing in on signals that promote blood vessel growth and cell changes driving progression, providing a smarter path when traditional chemotherapies lose steam. With immunotherapy ineffective for most MSS cases and resistance to VEGF inhibitors almost inevitable, this next-gen kinase inhibitor offers a logical evolution. In a field lacking fresh ideas for later-stage treatment, the survival boost from STELLAR-303 could make zanzalintinib the new go-to after initial therapies fail.
Looking ahead, lab studies hint that combining VEGFR2 and MET inhibition might boost immune responses by activating dendritic cells and cutting immunosuppressive forces in the tumor environment (Feng et al., Cancer Res, 2022). This fuels trials mixing zanzalintinib with checkpoint inhibitors, especially for MSS colorectal cancer's immune resistance. Plus, research extends to other cancers where MET or AXL matter, like kidney, liver, and certain bone cancers. As STELLAR-303 data solidifies and combo studies emerge, zanzalintinib could become a key player among multi-target TKIs fighting the overlapping defenses of advanced tumors. And this is the part most people miss: What if integrating it with immunotherapies unlocks cures for 'cold' cancers, challenging the notion that some tumors are untouchable?
In summary, zanzalintinib is a significant leap for treating MSS metastatic colorectal cancer, an area with scant advances. With better survival, gentler side effects than regorafenib, and a multi-pathway attack on resistance, it provides a thoughtful choice for those who've exhausted options. As upcoming research tests its teamwork with immunotherapies and use in other cancers, zanzalintinib might redefine targeted treatments. But here's where it gets controversial: In an era of rising drug prices, is prioritizing such innovations fair when it might widen disparities in access? What do you think—does this represent true progress, or are we overhyping incremental gains? Do you believe multi-target drugs like this are the future of oncology, or should we focus more on affordable, preventive measures? Share your opinions in the comments; let's discuss!
You Can Watch More on OncoDaily Youtube TV (https://youtu.be/F5Qs7AGlToQ?si=OYmj16NaxfOGhCnF)
Written by Armen Gevorgyan, MD
